Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease
- 14 January 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 23 (1), 93-101
- https://doi.org/10.1007/s10557-008-6148-1
Abstract
No abstract availableThis publication has 61 references indexed in Scilit:
- The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002)Journal of Lipid Research, 2009
- Inflammation and Plaque VulnerabilityCardiovascular Drugs and Therapy, 2008
- Leukotriene Signaling in Atherosclerosis and IschemiaCardiovascular Drugs and Therapy, 2008
- Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological EvidenceCardiovascular Drugs and Therapy, 2008
- Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)Cardiovascular Drugs and Therapy, 2008
- Biology of Secretory Phospholipase A2Cardiovascular Drugs and Therapy, 2008
- Highly Specific and Broadly Potent Inhibitors of Mammalian Secreted Phospholipases A2Journal of Medicinal Chemistry, 2008
- Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndromeAmerican Heart Journal, 2008
- Lipoprotein Associated Phospholipase A2 Inhibition Reduces Generation of Oxidized Fatty AcidsCardiovascular Drugs and Therapy, 2008
- Role of Group II Secretory Phospholipase A2in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 1999